查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375907

阴道炎治疗药物的市场规模、份额和趋势分析报告：按疾病类型、产品、地区和细分市场预测，2023-2030年

Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 75 Pages | 商品交期: 2-10个工作天内

价格

阴道炎治疗药物市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球阴道炎治疗市场规模将达到60亿美元，2023年至2030年年复合成长率为8.3%。

政府和非政府组织为提高妇女意识层级而做出的支持配合措施正在推动对阴道炎药物的需求。据估计，饮酒消费量的增加也刺激了这些药物的采用。美国约有 530 万名女性面临与健康和整体福祉相关的风险。

此外，阴道炎治疗药物研发活动的增加预计将加速市场成长。由美国过敏和感染疾病研究所 (NIAID) 资助的研究发现了有关酵母菌发育行为的重要资料，这可能会导致酵母菌感染疾病的新治疗方法。此外，主要企业推出新药预计将推动市场成长。例如，2017 年 9 月，Symbiomix Therapeutics 的 Solosec（塞克硝唑）获得 FDA核准，这是一种治疗细菌性阴道炎的药物。

阴道炎治疗药物市场报告亮点

  • 由于产品种类繁多以及细菌性阴道病病例数量不断增加，抗菌药物细分市场将在 2022 年以 37.9% 的销售份额引领阴道炎治疗药物市场。
  • 由于研发线产品的存在和产品采用率的增加，预计荷尔蒙在预测期内将以 8.4% 的年复合成长率实现良好增长。
  • 由于处方药的高效性和安全性以及针对严重和復发性阴道炎的多种药物的可用性，处方药细分市场在 2022 年以 51.2% 的最大销售份额引领市场。
  • 由于 FDA 对轻度阴道炎治疗的核准不断增加，成药领域预计未来年度将以 8.7%的年复合成长率扩张。
  • 由于优质的医疗服务和阴道炎患者数量的增加，北美地区在 2022 年将占销售额的 38.3%。
  • 预计亚太地区将呈现最快的成长，在预测期内年复合成长率约为 9.5%。这一增长得益于积极的政府配合措施、可支配所得的增加以及庞大的目标人口。

目录

第1章调查方法与范围

第2章执行摘要

第3章阴道炎治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 阴道炎治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章治疗药物市场：疾病类型估计及趋势分析

  • 阴道炎治疗药物市场：有关疾病类型的要点
  • 阴道炎治疗药物市场：2022年和2030年疾病类型趋势和市场占有率分析
  • 抗真菌剂
  • 抗菌的
  • 荷尔蒙

第5章阴道炎治疗药物市场：产品估算与趋势分析

  • 阴道炎治疗药物市场：产品要点
  • 阴道炎治疗药物市场：2022年和2030年产品趋势和市场占有率分析
  • 在商店
  • 处方笺

第6章阴道炎治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的阴道炎治疗药物市场：要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Symbiomix Therapeutics LLC.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Janssen Pharmaceuticals Inc.
    • Lupin Pharmaceuticals Inc.
    • Lumavita AG
    • Mission Pharmacal Company
Product Code: GVR-2-68038-604-2

Vaginitis Therapeutics Market Growth & Trends:

The global vaginitis therapeutics market size is expected to reach USD 6.0 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Vaginitis Therapeutics Market Report Highlights:

  • Anti-bacterial segment led the market for vaginitis therapeutics with a revenue share of 37.9% in 2022 owing to the availability of a wide product range and higher number of cases of bacterial vaginosis disease
  • Hormone is expected to witness lucrative growth with a CAGR of 8.4% over the forecast period due to the presence of pipeline products and rising adoption of products
  • The prescription segment led the market with the largest revenue share of 51.2% in 2022, owing to the higher efficacy and safety of prescribed drugs and availability of a wide range of drugs for severe and recurring vaginitis
  • Over the counter segment is expected to expand at a CAGR of 8.7% in the coming years due to increasing number of FDA approvals for the treatment of mild vaginitis
  • North America dominated the market with a revenue share of 38.3% in 2022, in terms of revenue, owing to of high-quality healthcare services and increasing cases of vaginitis
  • Asia Pacific is estimated to witness the fastest growth, with a CAGR of around 9.5% over the forecast period. This growth is attributed to favorable government initiatives and rising disposable income along with the presence of a large target population base.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease Type
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease Type outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Vaginitis Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis

  • 4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
  • 4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Anti-fungal
    • 4.3.1. Anti-fungal market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Anti-bacterial
    • 4.4.1. Anti-bacterial market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Hormone
    • 4.5.1. Hormone market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis

  • 5.1. Vaginitis Therapeutics Market: Product Key Takeaways
  • 5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Over-the-counter
    • 5.3.1. Over-the-counter market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Denmark
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Symbiomix Therapeutics LLC.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Merck & Co., Inc.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis AG
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Teva Pharmaceutical Industries Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bayer AG
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Janssen Pharmaceuticals Inc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Lupin Pharmaceuticals Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Lumavita AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Mission Pharmacal Company
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 3 North America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 6 U.S. vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 8 Canada vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 10 Europe vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 13 Germany vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 15 UK vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 16 France vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 17 France vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 19 Italy vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 21 Spain vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 23 Sweden vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Norway vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 27 Denmark vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 32 China vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 34 Japan vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 35 India vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 36 India vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 38 Australia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 40 Thailand vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 42 South Korea vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 44 Latin America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 47 Brazil vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 49 Mexico vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 51 Argentina vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 56 South Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 60 UAE vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Vaginitis Therapeutics: Market outlook
  • Fig. 9 Vaginitis Therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Vaginitis Therapeutics market driver impact
  • Fig. 15 Vaginitis Therapeutics market restraint impact
  • Fig. 16 Vaginitis Therapeutics market strategic initiatives analysis
  • Fig. 17 Vaginitis Therapeutics market: Disease type movement analysis
  • Fig. 18 Vaginitis Therapeutics market: Disease type outlook and key takeaways
  • Fig. 19 Anti-fungal market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Anti-bacterial market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Hormone market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Vaginitis Therapeutics market: Product movement analysis
  • Fig. 23 Vaginitis Therapeutics market: Product outlook and key takeaways
  • Fig. 24 Over-the-counter market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Prescription (Rx) market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Vaginitis Therapeutics market: Regional movement analysis
  • Fig. 27 Global Vaginitis Therapeutics market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)